Insulin Patch Pump Market: Tech Progress

1
Insulin Patch Pump Market Tech Progress

• Insulin therapy is an important aspect of
  diabetes management and treatment. Today, a
  number of insulin delivery systems, in the form
  of pens, syringes, jet injectors, pumps, etc.,
  are used by patients to regulate blood sugar
  levels. Nowadays, they are increasingly opting
  for patch pumps or tubeless pumps, which are
  compact digital devices that deliver insulin
  doses at regular intervals. The global insulin
  patch pump market is expected to progress with a
  CAGR of 10.54 in the forecast period from 2023
  to 2030.
• The markets growth can be attributed to the
  rising popularity of these skin-adhesive devices,
  surging diabetes prevalence, demand for minimally
  invasive systems, and increased efforts in RD.
  Patch pumps are also more accurate, efficient,
  affordable, and easier to use than conventional
  insulin delivery pumps. These products are
  available in disposable as well as reusable
  formats, and can function optimally with minimum
  monitoring. Also, their discrete nature is one of
  the key factors that has increased their adoption
  among younger patients.

Whats Influencing Market Growth? The global
burden of diabetes mellitus has burgeoned in
recent years, owing to changing lifestyles,
rising obesity rates, increasing geriatric
population, and unhealthy eating habits. As of
2021, more than 537 million adults worldwide were
reported to have diabetes, according to the
International Diabetes Federation (IDF). And with
over 74.2 million patients, India accounts for 1
in 7 of all adults affected by the condition.
2
Moreover, with 165.3 billion in 2021, China
accounted for one of the highest diabetes-related
healthcare expenditures. The rising
diabetes-related healthcare expenditure has
consequently increased patient demand for
self-management options for diabetes in the
region. This is expected to aid the Asia- Pacific
insulin patch pump markets development, with a
10.94 CAGR over the forecast period. Insulated
by Insulin Investments Boost Product
Development In view of increased spending by
consumers, the market faces a higher demand for
innovative insulin delivery patch pumps. For
instance, JewelPUMP by Debiotech SA is a highly
miniaturized insulin delivery patch pump with
temperature sensors dedicated for use by both
type 1 and type 2 diabetes patients. While type 1
diabetics comprise a small portion of the total
diabetes patient pool, compared to their type 2
counterparts, they are more dependent on insulin
therapy. Their pancreas produce little to no
insulin, which makes regular insulin intake vital
for their survival. In this case, patch pumps are
handy as they eliminate the need to carry an
insulin infusion set. Type 1 diabetes is expected
to grow with the fastest CAGR of 11.08 in the
disease indication segment during 2023-2030. In
2017, the government-backed Canadian Institutes
of Health Research (CIHR) and the Juvenile
Diabetes Research Foundation (JDRF) Canada
announced the CIHR-JDRF Partnership to Defeat
Diabetes, with an investment of 30 million in
advanced research for type 1 diabetes. This
partnership was further renewed, with an
additional investment of 15 million in
2021. Increased investments, coupled with the
growing patient demand for accessing health data
in a user- friendly format, have led to the
development of smart solutions for diabetes care.
For instance, in March 2022, Terumo Corporation
partnered with SaaS-based app developer Glooko.
This has improved the quality of remote patient
monitoring, as the users of Terumos Medisafe
With insulin patch pump can transfer their data
on Glookos analytics portal, allowing healthcare
professionals to view their patients latest
health records. AI ML Technologies Pushing the
Frontiers in Diabetes Care The rising usage of
fitness tracking apps, smart wearables, and
connected devices by patients to gain real-time
insights have paved the way for advanced and
technologically-integrated healthcare. For
instance, machine learning uses physiological or
activity sensors embedded into smart devices or
wearables to deliver personalized therapy, which
helps lower hyperglycemia and minimize the
overall burden. In addition, the MiniMed 780G by
Medtronic Plc is an advanced patch pump that uses
artificial intelligence (AI) to automate insulin
delivery. It is incorporated with SmartGuard
automation for self- adjusting basal delivery
with auto-correction dosing and administering
bolus insulin. Particularly, the real-time data
offered by such technologies has enabled
effective remote monitoring of older or
specially-abled patients. Improved patient
outcomes and experience are thus expected to
drive the global AI in healthcare market at a
CAGR of 40.48 from 2019 to 2027. In a
Nutshell Over the years, diabetes management
solution providers have worked to keep up with
the evolving needs of diabetic patients. With
users increasing knowledge and understanding of
their condition, companies have responded by
upgrading their insulin delivery devices,
leveraging the power of
3
technology. For instance, integrating insulin
patch pumps with continuous glucose monitoring
systems has optimized pump use and improved
glycemic response. Such innovations by
manufacturers are expected to propel the insulin
patch pump market on a growth path. FAQs Q 1)
Which are the key segments considered in the
market report? Product Type, Disease Indication,
Delivery Mode, and Distribution Channel. Q 2)
Which country is expected to register the fastest
growth rate in the global insulin patch pump
market? Australia is expected to exhibit the
fastest growth globally, with a CAGR of 12.28
over the forecast period.